{"id":183315,"date":"2017-03-17T06:48:06","date_gmt":"2017-03-17T10:48:06","guid":{"rendered":"http:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/what-a-genome-wide-screening-can-reveal-about-cancer-survival-lawrence-berkeley-national-laboratory\/"},"modified":"2017-03-17T06:48:06","modified_gmt":"2017-03-17T10:48:06","slug":"what-a-genome-wide-screening-can-reveal-about-cancer-survival-lawrence-berkeley-national-laboratory","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/transhuman-news-blog\/genome\/what-a-genome-wide-screening-can-reveal-about-cancer-survival-lawrence-berkeley-national-laboratory\/","title":{"rendered":"What a Genome-Wide Screening Can Reveal about Cancer Survival &#8211; Lawrence Berkeley National Laboratory"},"content":{"rendered":"<p><p>    What if a simple genetic test could tell cancer patients what    their odds of survival are? Its an approach that researchers    at the Department of Energys Lawrence Berkeley National    Laboratory are developing, and they have made significant    inroads in several types of cancer, most recently for breast    cancer.  <\/p>\n<p>      Berkeley Lab researchers have developed a genetic score      reflecting the prognosis for specific types of breast cancer.      The score is based upon a 12-gene signature identified      through analysis of large genomic datasets and clinical      patient data. (Credit: iStockphoto)    <\/p>\n<p>    After analyzing large genomic datasets and clinical patient    data, scientists at Berkeley Lab found the expression of 381    genes to be significantly associated with relapse-free survival    in breast cancer patients.  <\/p>\n<p>    They further narrowed down the data to a 12-gene signature and    developed a scoring system that would help predict patient    prognosis. Low scores were linked with higher chances of    survival past 20 years, while high scores correlated with lower    survival rates. The results were     reported recently in the journal Oncotarget.  <\/p>\n<p>    Distinguishing patients with good prognosis could potentially    spare them the toxic side effects associated with adjuvant    therapy, said study corresponding author Antoine Snijders, a    research scientist at Berkeley Labs Biological Systems and    Engineering Division. Determining prognosis involves a range    of other clinical factors, including tumor size and grade, the    degree to which the cancer has spread, and the age and race of    the patient. Our scoring system was predictive of survival    independent of these other variables.  <\/p>\n<p>    The signature was most effective for two specific subtypes of    breast cancer: HER2 and Luminal A.  <\/p>\n<p>    Among women in the United States, breast cancer is the most    common cancer and the second leading cause of cancer deaths,    according to the Centers for Disease Control and Prevention.    Death rates have dropped in recent decades; the chance is now 1    in 37 that a woman will die from breast cancer.  <\/p>\n<p>    There is obviously a lot of variability in mortality rates,    but this paper presents a path towards getting more information    specific to an individual, said Snijders.  <\/p>\n<p>    Researchers have been taking advantage of advances in    computational biology and genome-wide screening techniques to    identify genetic signatures for cancer prognosis. In 2016,    another Berkeley Lab group     found a potential new biomarker for early stages of tumor    development in a wide variety of cancers.  <\/p>\n<p>    Such scoring systems could be developed into an additional tool    to help doctors and patients make informed decisions about the    course of treatment.  <\/p>\n<p>    The authors of this study included Xuan Mao, Matthew Lee,    Jeffrey Zhu and Carissa Zhu, all students from Campolindo High    School in Moraga, California, who worked as interns at Berkeley    Lab in 2016. Under the supervision of Snijders, they led the    programming effort and computational analysis that helped    identify the relevant genes and that formed the basis of the    scoring system.  <\/p>\n<p>    Snijders says future steps include multi-center prospective    studies to validate the scoring system in clinical settings.  <\/p>\n<p>    ###  <\/p>\n<p>    Lawrence Berkeley National Laboratory addresses the worlds    most urgent scientific challenges by advancing sustainable    energy, protecting human health, creating new materials, and    revealing the origin and fate of the universe. Founded in 1931,    Berkeley Labs scientific expertise has been recognized with 13    Nobel Prizes. The University of California manages Berkeley Lab    for the U.S. Department of Energys Office of Science. For    more, visitwww.lbl.gov.  <\/p>\n<p>    DOEs Office of Science is the single largest supporter of    basic research in the physical sciences in the United States,    and is working to address some of the most pressing challenges    of our time. For more information, please visitscience.energy.gov.  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>Read this article:<br \/>\n<a target=\"_blank\" href=\"http:\/\/newscenter.lbl.gov\/2017\/03\/13\/genome-wide-screening-cancer-survival\/\" title=\"What a Genome-Wide Screening Can Reveal about Cancer Survival - Lawrence Berkeley National Laboratory\">What a Genome-Wide Screening Can Reveal about Cancer Survival - Lawrence Berkeley National Laboratory<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> What if a simple genetic test could tell cancer patients what their odds of survival are? Its an approach that researchers at the Department of Energys Lawrence Berkeley National Laboratory are developing, and they have made significant inroads in several types of cancer, most recently for breast cancer.  <a href=\"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/transhuman-news-blog\/genome\/what-a-genome-wide-screening-can-reveal-about-cancer-survival-lawrence-berkeley-national-laboratory\/\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[25],"tags":[],"class_list":["post-183315","post","type-post","status-publish","format-standard","hentry","category-genome"],"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/183315"}],"collection":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/comments?post=183315"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/183315\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/media?parent=183315"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/categories?post=183315"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/tags?post=183315"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}